9MW-2821
- Generic Name
- 9MW-2821
A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- Drug: Other anti-cancer therapy
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 188
- Registration Number
- NCT06947226
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
- Conditions
- Urothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma RecurrentUrothelial Carcinoma of the Renal Pelvis and Ureter
- Interventions
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT06823427
- Locations
- 🇨🇳
Hunan Tumor Hospital, Changsha, Hunan, China
🇨🇳Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 420
- Registration Number
- NCT06692166
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2024-09-12
- Last Posted Date
- 2024-09-12
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 460
- Registration Number
- NCT06592326
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Target Recruit Count
- 30
- Registration Number
- NCT06551233
- Locations
- 🇨🇳
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- Drug: PD-1 inhibitior
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT06492005
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
- Conditions
- Advanced Urothelial Carcinoma
- Interventions
- Drug: Chemotherapy
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 432
- Registration Number
- NCT06196736
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
- Conditions
- Advanced Urothelial Carcinoma
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06079112
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05773937
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Beijing University Cancer Hospital, Beijing, Beijing, China
A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 208
- Registration Number
- NCT05216965
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.